Silence Therapeutics【SLN】銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

6.54

買値

6.35

売値

7.09

出来高

979,961

6.16 日の範囲 7.09

0.00 52 週間の範囲 0.00

時価総額

306.072M

前日終値

6.34

始値

6.2732

時刻

6.66

最終取引時間

財務取引量

US$ 6,628,868

VWAP

6.7644

平均取引量 (3 か月)

発行済株式数

46,800,000

配当利回り

PER

-2.16

1 株当たり利益 (EPS)

-0.92

歳入

25.38M

純利益

-43.27M

Silence Therapeutics PLC is one of the leading companies in the ribonucleic acid (RNA) technology field. The United Kingdom-based firm focused on discovering and developing novel molecules incorporating short interfering ribonucleic acid, or siRNA, to inhibit the expression of specific target genes ... Silence Therapeutics PLC is one of the leading companies in the ribonucleic acid (RNA) technology field. The United Kingdom-based firm focused on discovering and developing novel molecules incorporating short interfering ribonucleic acid, or siRNA, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical needs. Its income consists of royalty income and revenue from collaboration agreements. Its geographical segments are the United Kingdom, the United States, and Germany. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

本社

London, Gbr

設立

Silence Therapeutics PLC is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker SLN. The last closing price for Silence Therapeutics was US$6.34. Over the last year, Silence Therapeutics shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Silence Therapeutics currently has 46,800,000 shares in issue. The market capitalisation of Silence Therapeutics is US$296.71 million. Silence Therapeutics has a price to earnings ratio (PE ratio) of -2.16.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

New divesiran data continue to show substantial reduction in phlebotomy frequency and lowering of hematocrit levels in PV patients Silence also announces first subject dosed in Phase 2 study of...

Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

New zerlasiran data show significant time-averaged Lp(a) reductions with effects persisting 60 weeks following the first dose Represents first study to report time-averaged Lp(a) results to...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

SLN - Frequently Asked Questions (FAQ)

What is the current Silence Therapeutics share price?

The current share price of Silence Therapeutics is US$ 6.54

How many Silence Therapeutics shares are in issue?

Silence Therapeutics has 46,800,000 shares in issue

What is the market cap of Silence Therapeutics?

The market capitalisation of Silence Therapeutics is USD 296.71M

What is the 1 year trading range for Silence Therapeutics share price?

Silence Therapeutics has traded in the range of US$ 0.00 to US$ 0.00 during the past year

What is the PE ratio of Silence Therapeutics?

The price to earnings ratio of Silence Therapeutics is -2.16

What is the cash to sales ratio of Silence Therapeutics?

The cash to sales ratio of Silence Therapeutics is 3.69

What is the reporting currency for Silence Therapeutics?

Silence Therapeutics reports financial results in GBP

What is the latest annual turnover for Silence Therapeutics?

The latest annual turnover of Silence Therapeutics is GBP 25.38M

What is the latest annual profit for Silence Therapeutics?

The latest annual profit of Silence Therapeutics is GBP -43.27M

What is the registered address of Silence Therapeutics?

The registered address for Silence Therapeutics is 27 EASTCASTLE STREET, LONDON, W1W 8DH

Which industry sector does Silence Therapeutics operate in?

Silence Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
MYSZMy Size Inc	US$ 4.2001 (211.12%)	120.01M
NVNINVNI Group Ltd	US$ 8.26 (209.36%)	76.64M
TPICTPI Composites Inc	US$ 2.45 (100.82%)	33.95M
ICGIntchains Group Ltd	US$ 8.77 (88.60%)	527.61k
HSDTHelius Medical Technologies Inc	US$ 0.884851 (84.34%)	120.4M
CYNCYNGN Inc	US$ 0.4603 (-71.41%)	27.9M
MTEMMolecular Templates Inc	US$ 0.1502 (-57.09%)	8.75M
PRFXPainReform Ltd	US$ 5.15 (-53.85%)	2.94M
GALTGalectin Therapeutics Inc	US$ 1.03 (-48.50%)	9.27M
BCABBioAtla Inc	US$ 0.6923 (-41.82%)	6.25M
EDBLEdible Garden AG Inc	US$ 0.24 (65.06%)	354.27M
APTOAptose Biosciences Inc	US$ 0.28 (64.51%)	305.1M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.606999 (6.49%)	292.16M
NVDANVIDIA Corporation	US$ 134.70 (3.08%)	287.21M
PLTRPalantir Technologies Inc	US$ 80.55 (8.54%)	277.63M